Abstract
Aims: Saudi Arabia’s ongoing health sector transformation is expanding private health insurance, yet its relationship with diabetes outcomes is unclear. We examined the association of private insurance with use of newer therapies and glycemic and cardiometabolic outcomes among people with diabetes (PWD). Methods: A retrospective cross-sectional analysis of data from 311 PWD, managed by the same endocrinologist at a public and a private tertiary center (November 2021-November 2022). Participants without private insurance (publicly covered) remained entitled to free care at public facilities. Results: Overall, 40.19% of participants were privately insured; 85.60% of them attended the private clinic, whereas 97.85% of publicly covered PWD attended the public clinic. Prescription of GLP-1 RA, SGLT-2 inhibitors, and combined diabetes medications was more common among privately insured PWD (all p < 0.01), as was achieving A1C ≤ 8.0% (64.66% vs. 31.84%, p < 0.01). Private insurance was associated with greater odds of achieving A1C ≤ 8.0% [OR (95% CI): 2.57 (1.26, 5.26)] after adjusting for sociodemographic and clinical factors and utilization of newer diabetes medications and technology. Conclusions: Private health insurance, together with care in the private healthcare setting, was associated with better glycemic outcomes among PWD in Saudi Arabia. Because insurance status was closely linked to the care setting, this association likely reflects coverage-, institution-, and patient-level factors. As insurance coverage expands, monitoring outcomes across insurance groups and care settings may help narrow existing gaps.